SEC Tracker
Get the app
OTLK · XBRL financial data

Outlook Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (OTLK's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Apr 15, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Revenue from contracts with customers———————1,505(92)*———
Cost of goods and services sold———————440year only3014917
Gross profit———————1,066—(1,237)(22)(8)
Research and development4,944*4,529—11,20212,523*9,6604,4077,1355,979*3,6344,5013,251
Selling, general and administrative———8,36110,354*11,9477,9859,67910,328*8,6129,5057,551
General and administrative7,515*5,794—8,36110,354*11,9477,985—————
Total operating expenses———19,563————————
Operating income (loss)(12,459)*(10,323)—(19,563)(22,877)*(21,607)(12,392)(15,749)(17,315)*(13,484)(14,027)(10,810)
Interest income306*——405240*———year only———
Interest expense0*———0*———————
Income tax expense (benefit)0*——0*0*—30*(1,555)*———
Net income (loss)(12,991)*(11,178)—44,4095,691*17,378(46,357)(20,153)(13,293)*(23,058)(4,453)(20,319)
Earnings per share, basic‡ USD per share(1.00)*(0.80)—1.91—0.72(1.50)(0.55)—(0.38)(0.05)(0.15)
Earnings per share, diluted‡ USD per share(1.00)*(0.80)—(0.89)—0.72(1.50)(0.55)—(0.38)(0.05)(0.15)
Weighted average shares, basic‡ thousands of shares12,998*13,013—23,227—24,23430,87436,957—60,20581,836136,743
Weighted average shares, diluted‡ thousands of shares12,998*13,013—25,47621,464*24,23430,87436,957—60,20581,836136,743
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (March 2024); filings made before it reported them unadjusted.
  • † Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (OTLK's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Apr 15, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Cash and cash equivalents23,39210,357—32,02414,9285,7037,5568,9018,0838,6777,74811,242
Accounts receivable———————1,7511,4911152,7201,644
Inventory—————3,1093,6054,1273,3383,4583,3445,044
Prepaid and other current assets7,58710,033—13,59312,4886,8556,6466,3174,4774,9167,0925,238
Total current assets30,97920,389—45,61827,41615,66717,80721,09617,38917,16720,90523,168
Right-of-use asset2615—286275263251238226212199185
Total assets32,30121,685—47,09228,82317,00619,07522,39218,58418,23921,89226,185
Accounts payable6,5753,480—5,5527,96912,1937,76610,26210,1927,31913,6366,807
Accrued liabilities2,7464,087—2,6813,2373,3913,1455,3145,3144,7149,0393,279
Total current liabilities46,73245,969—42,55442,55448,23724,82231,48945,81549,05638,88428,679
Lease liability, non-current———260247233219204189172157140
Total liabilities46,73846,028—130,765101,90067,29651,53859,58150,77256,78850,88736,577
Accumulated deficit(467,918)(479,096)—(548,976)(543,285)(525,907)(572,264)(592,417)(605,710)(628,768)(633,221)(653,540)
Total stockholders' equity(14,438)(24,343)—(83,673)(73,077)(50,290)(32,463)(37,190)(32,188)(38,549)(28,995)(10,393)
Total liabilities and equity32,30121,685—47,09228,82317,00619,07522,39218,58418,23921,89226,185
Common shares outstanding (cover page)‡ thousands of shares13,01313,01323,40623,65624,90632,01733,56844,42064,11483,067120,863243,448
  • ‡ Per-share figures and share counts are adjusted for the 1-for-20 stock split (March 2024); filings made before it reported them unadjusted.
  • † Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (OTLK's year ends in late September)

In thousands of dollarsSep 30, 2023Dec 31, 2023Apr 15, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026†Jun 30, 2026
Net income (loss)(12,991)*(11,178)—44,4095,691*17,378(46,357)(20,153)(13,293)*(23,058)(4,453)(20,319)
Stock-based compensation1,389*1,273—1,396*1,406*3,6721,723*1,682*1,821*881757*792*
Net cash from operating activities(12,741)*(13,032)—(19,512)*(16,982)*(10,967)(16,584)*(11,901)*(12,377)*(14,939)(7,828)*(21,011)*
Proceeds from issuing common stock2,427*——4,308*(115)*1,7421,416*14,153*8,085*14,9326,899*25,196*
Net cash from financing activities2,424*(3)—4,308*(115)*1,74218,437*13,246*11,559*15,5336,899*26,604*
Net change in cash(10,317)*(13,035)—(15,205)*(17,097)*(9,225)1,854*1,345*(818)*594(929)*3,494*
  • † Share count changed about 2x in the period ending 2026-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Outlook Therapeutics11,242not reported(21,011)*243.4M0.5 quarters 10-QJun 30, 2026
OnKure Therapeutics166,502not reported(10,354)*40.5M17.0 quarters 10-QJun 30, 2026
Palatin Technologies7,492301*(2,690)*1.8M2.8 quarters 10-KJun 30, 2026
Scynexis10,487235(14,885)*9.9M3.6 quarters 10-QJun 30, 2026
Champions Oncology4,35815,232(492)13.9M8.0 quarters 10-QJul 31, 2026
Rockwell Medical10,519not reported2,080*4.0M— 10-QJun 30, 2026
Pulmatrix2,168not reported(1,106)*3.7M2.0 quarters 10-QJun 30, 2026
Curis5,0730(9,646)*2.1M0.5 quarters 10-QJun 30, 2026
Cumberland Pharmaceuticals3,862166169*15.0M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.